Author | Nichole Tucker

Articles

Sacituzumab Govitecan Brings Long-Awaited Progress in the Treatment Landscape of mTNBC

May 25, 2020

Article

In an interview with Targeted Oncology following the announcement of sacituzumab govitecan accelerated FDA approval, Hope Rugo, MD, discussed the published data from the phase 1/2 basket trial and the relevance of having sacituzumab govitecan available for the treatment of patients with metastatic triple negative breast cancer.

Neoadjuvant Atezolizumab With Chemotherapy Feasible in Advanced NSCLC

May 24, 2020

Article

"Our trial, together with ongoing randomized trials, provides more evidence on the risks and benefits of immunotherapy as a neoadjuvant treatment, and could help to answer questions regarding the optimal duration, best surrogate endpoint, and best predictive biomarkers for treatment."

Positive Responses With Belumosudil in GVHD Spark Pending FDA Submission

May 21, 2020

Article

"These results demonstrate the potential of belumosudil to become a cornerstone of the cGVHD treatment paradigm if approved, as it delivers meaningful and sustained benefits to patients with this serious condition."

Durvalumab/Chemotherapy Combination Improves Survival in Mesothelioma

May 21, 2020

Article

"Durvalumab plus standard chemotherapy delivered a promising median overall survival rate for patients with previously untreated, inoperable malignant pleural mesothelioma."